Updating results

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance Published July 2014

The geko device for reducing the risk of venous thromboembolism (MTG19)

Evidence-based recommendations on the geko device for reducing the risk of venous thromboembolism (VTE)

Medical technologies guidance Published June 2014

Canagliflozin in combination therapy for treating type 2 diabetes (TA315)

Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes

Technology appraisal guidance Published June 2014

Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure (TA314)

Evidence-based recommendations on implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy (CRT) for arrhythmias and heart failure

Technology appraisal guidance Published June 2014

The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

Evidence-based recommendations on the MAGEC system for spinal lengthening in children with scoliosis (curvature of the spine)

Medical technologies guidance Published June 2014

Teriflunomide for treating relapsing–remitting multiple sclerosis (TA303)

Evidence-based recommendations on teriflunomide (Aubagio) for treating relapsing–remitting multiple sclerosis (RRMS/MS) in adults

Technology appraisal guidance Published January 2014 Last updated June 2014

Alemtuzumab for treating relapsing‑remitting multiple sclerosis (TA312)

Evidence-based recommendations on alemtuzumab (Lemtrada) for treating active relapsing–remitting multiple sclerosis (MS)

Technology appraisal guidance Published May 2014

Ustekinumab for treating active psoriatic arthritis (TA313)

This guidance has been updated and replaced by NICE technology appraisal guidance 340.

Technology appraisal guidance Published May 2014

Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

Evidence-based recommendations on bortezomib (Velcade) for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell..

Technology appraisal guidance Published April 2014

Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (TA310)

Evidence-based recommendations on afatinib (Giotrif) for treating EGFR-TK mutation-positive locally advanced or metastatic non-small-cell lung cancer..

Technology appraisal guidance Published April 2014

Measuring fractional exhaled nitric oxide concentration in asthma: NIOX MINO, NIOX VERO and NObreath (DG12)

Evidence-based recommendations on the NIOX MINO, NIOX VERO and Nobreath devices to measure fractional exhaled nitric oxide concentration in asthma

Diagnostics guidance Published April 2014

Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (TA308)

Evidence-based recommendations on rituximab (MabThera) with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis

Technology appraisal guidance Published March 2014

Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)

Evidence-based recommendations on aflibercept (Zaltrap) with FOLFIRI for metastatic colorectal cancer that has progressed after oxaliplatin

Technology appraisal guidance Published March 2014

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)

Evidence-based recommendations on total hip replacement and resurfacing arthroplasty for treating end-stage arthritis of the hip

Technology appraisal guidance Published February 2014

Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma (TA306)

Evidence-based recommendations on pixantrone (Pixuvri) for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma

Technology appraisal guidance Published February 2014

Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)

NICE is unable to make a recommendation about the use in the NHS of canakinumab drug name (Ilaris) for systemic juvenile idiopathic arthritis..

Technology appraisal guidance Published November 2013

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (TA301)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema after prior therapy

Technology appraisal guidance Published November 2013

Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (TA300)

Evidence-based recommendations on peginterferon alfa and ribavirin (Pegasys) for treating chronic hepatitis C in children and young people

Technology appraisal guidance Published November 2013

Bosutinib for previously treated chronic myeloid leukaemia (TA299)

This guidance has been updated and replaced by NICE technology appraisal guidance 401

Technology appraisal guidance Published November 2013

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance Published November 2013

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Ocriplasmin for treating vitreomacular traction (TA297)

Evidence-based recommendations on ocriplasmin (Jetrea) for treating vitreomacular traction in adults

Technology appraisal guidance Published October 2013

Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (DG11)

Evidence-based recommendations on faecal calprotectin diagnostic tests for inflammatory diseases of the bowel

Diagnostics guidance Published October 2013

EGFR‑TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (DG9)

Evidence-based recommendations on EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC)

Diagnostics guidance Published August 2013

Intraoperative tests (RD‑100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer (DG8)

Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in breast cancer

Diagnostics guidance Published August 2013

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

Evidence-based recommendations on aripiprazole (Abilify) for treating moderate to severe manic episodes in adolescents with bipolar I disorder

Technology appraisal guidance Published July 2013

Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)

Evidence-based recommendations on aflibercept (Eylea) solution for injection for treating wet age-related macular degeneration

Technology appraisal guidance Published July 2013

Vision Amniotic Leak Detector to assess unexplained vaginal wetness in pregnancy (MTG15)

In March 2019, NICE reviewed this guidance and recommended it should be withdrawn because Vision Amniotic Leak Detector is no longer available. NICE has produced a medtech innovation briefing on AmnioSense for unexplained vaginal wetness in pregnancy. For a copy of the review decision, please contact nice@nice.org.uk.

Medical technologies guidance Published July 2013

Pegloticase for treating severe debilitating chronic tophaceous gout (TA291)

The guidance has been withdrawn because pegloticase (Krystexxa) no longer has a marketing authorisation. See the European Medicines Agency product information.

Technology appraisal guidance Published June 2013

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis (TA289)

This guidance has been updated and replaced by NICE technology appraisal guidance 386.

Technology appraisal guidance Published June 2013

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance Published June 2013

Loxapine inhalation for treating acute agitation and disturbed behaviours associated with schizophrenia and bipolar disorder (terminated appraisal) (TA286)

NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with

Technology appraisal guidance Published May 2013

Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)

Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of

Technology appraisal guidance Published May 2013

Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (TA284)

Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer

Technology appraisal guidance Published May 2013

Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion (TA283)

Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance Published May 2013

Pirfenidone for treating idiopathic pulmonary fibrosis (TA282)

This guidance has been updated and replaced by NICE technology appraisal guidance 504.

Technology appraisal guidance Published April 2013

Canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks (terminated appraisal) (TA281)

NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks

Technology appraisal guidance Published April 2013

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal) (TA277)

NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...

Technology appraisal guidance Published March 2013

Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis (TA276)

Evidence-based recommendations on colistimethate sodium and tobramycin dry powders for inhalation for pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance Published March 2013